Grouped-seq verification data and CRC organoid drug test sequencing data

Patient-derived tumor organoids (PDOs) have emerged as a reliable in vitro model for drug discovery. However, RNA sequencing-based analysis of PDOs treated with drugs has not been realized in a high-throughput format due to the limited quantity of organoids. Here we translated a newly developed pooled RNA-seq methodology onto a superhydrophobic microwell array chip to realize an assay of genome-wide RNA output unified with phenotypic data (Grouped-seq).To verify the feasibility of Grouped-seq, we designed several assays from all aspects, such as homogeneity, accuracy and sensitivity. To explore the further application of Grouped-seq, we used Grouped-seq to derive the mechanism of various drugs delivered to CRC organoid.